Form 4: Neurocrine Biosciences Insider Trades Common Stock

Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences, executed a series of transactions involving the purchase and sale of company common stock, primarily under a Rule 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc. (NBIX), engaged in multiple transactions involving the company's common stock between July 7, 2026, and July 9, 2026.
• These transactions included the purchase of common stock at $103.52 per share on three separate dates, totaling 14,571 shares.
• Concurrently, Delaet disposed of common stock, with sales occurring at weighted average prices ranging from $178.52 to $179.19 per share.
• The dispositions were executed through a broker pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026.
• Following these transactions, Delaet's beneficial ownership of common stock is reported as 16,225 shares directly held.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of stock by a high-ranking executive, despite the transactions being conducted under a pre-established trading plan.

Positives

• The reporting person purchased shares, indicating a potential belief in the company's value at the purchase price.
• The transactions were conducted under a Rule 10b5-1 trading plan, suggesting pre-planned and potentially less opportunistic trading activity.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale price per share ($178.52 - $179.19) was substantially higher than the purchase price ($103.52), indicating a large profit for the executive on these specific transactions.

Risks

• The disposition of shares by a Chief Regulatory Officer could be interpreted as a lack of confidence in future stock performance, although executed under a 10b5-1 plan.
• The company's policy restricts modification of 10b5-1 plans after adoption, which could limit flexibility in response to unforeseen market changes.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of trades under a Rule 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances while adhering to insider trading regulations, particularly in the biopharmaceutical sector where stock-based compensation is prevalent.

Corporate Governance

Stakeholder Impact

• Shareholders may view the sale of a significant number of shares by a Chief Regulatory Officer with some concern, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees may interpret the executive's transactions as a signal regarding the company's future prospects.

Next Steps

• Continued monitoring of insider trading activity for Neurocrine Biosciences Inc.

Key Dates

Keywords

Form 4, Insider Trading, Neurocrine Biosciences, NBIX, Common Stock, Rule 10b5-1, Stock Options, Beneficial Ownership, Executive Transactions, Securities Exchange Act